Featured 13F manager
Farallon Capital Management, L.l.c.
San Francisco, CA 87 processed 13Fs on this site · 2021 Q3–2026 Q2
- $21.7B
- 77 Positions
- 2026 Q2
- +23.6% QoQ
- Top 5 29.9%
Portfolio
top 5 29.9% · top 10 44.0%
- RVMD - Revolution Medicines 11.7%
- EA - Electronic Arts 7.5%
- BBIO - Bridgebio Pharma 3.7%
- PTGX - Protagonist Therapeutics 3.6%
- EXEL - Exelixis 3.4%
- LQDA - Liquidia 3.1%
- AMZN - Amazon 2.9%
- LNTH - Lantheus 2.9%
- NTRA - Natera 2.8%
- UNH - Unitedhealth Group 2.4%
- TMO - Thermo Fisher Scientific 2.4%
- ROIV - Roivant Sciences 2.3%
- Other 51.3%
AUM over time
Book
| IQV - IQVIA | 4.41% | Add +8.4% | 2,930,756 | $282.14 | $827M | +227,000 | +$179M |
| BSX - Boston Scientific | 3.81% | Add +20.1% | 16,814,581 | $42.48 | $714M | +2,812,000 | +$107M |
| GOOG - Alphabet · CL C | 3.54% | Add +26.9% | 228,957 | $2,894 | $663M | +48,500 | +$182M |
| ARMK - Aramark | 3.53% | Reduce −1.9% | 17,962,483 | $36.85 | $662M | −355,173 | +$60M |
| TMO - Thermo Fisher Scientific | 3.46% | Reduce −0.7% | 972,959 | $667.24 | $649M | −6,700 | +$89M |
| WAB - Wabtec | 3.07% | Add +5.0% | 6,241,151 | $92.11 | $575M | +296,000 | +$62M |
| HWM - Howmet Aerospace | 2.81% | Add +58.8% | 16,531,453 | $31.83 | $526M | +6,123,453 | +$201M |
| RTX - Raytheon Technologies | 2.65% | Add +10.7% | 5,775,386 | $86.06 | $497M | +560,400 | +$49M |
| META - Meta Platforms · CL A | 2.45% | Add +28.2% | 1,366,545 | $336.35 | $460M | +300,800 | +$98M |
| MSFT - Microsoft | 2.44% | Reduce −10.0% | 1,361,278 | $336.32 | $458M | −151,300 | +$31M |
| BHP Group | 2.16% | Add +6.8% | 6,785,000 | $59.77 | $406M | +431,000 | +$83M |
| NYT - New York Times · CL A | 2.15% | Add +2.5% | 8,336,258 | $48.30 | $403M | +200,000 | +$2M |
| MA - Mastercard · CL A | 2.13% | Add +17.4% | 1,113,300 | $359.32 | $400M | +165,200 | +$70M |
| AON - AON PLC · CL A | 1.91% | Reduce −5.5% | 1,193,486 | $300.56 | $359M | −68,829 | −$2M |
| CNC - Centene Del | 1.91% | Reduce −5.1% | 4,339,344 | $82.40 | $358M | −233,531 | +$73M |
| ELV - Anthem | 1.87% | Reduce −11.7% | 755,060 | $463.54 | $350M | −99,905 | +$31M |
| SHW - Sherwin Williams | 1.79% | Reduce −1.9% | 951,068 | $352.16 | $335M | −18,800 | +$64M |
| TRU - Transunion | 1.76% | Add +37.3% | 2,789,182 | $118.58 | $331M | +757,200 | +$103M |
| NOW - Servicenow | 1.74% | Add +1.4% | 503,150 | $649.11 | $327M | +6,850 | +$18M |
| AVGO - Broadcom | 1.71% | Reduce −26.1% | 481,000 | $665.41 | $320M | −169,500 | +$5M |
| BX - Blackstone | 1.65% | Reduce −9.9% | 2,395,336 | $129.39 | $310M | −264,200 | +$523K |
| V - VISA · CL A | 1.64% | Add +13.8% | 1,414,604 | $216.71 | $307M | +171,100 | +$30M |
| EFX - Equifax | 1.57% | Add +12.7% | 1,005,183 | $292.79 | $294M | +113,600 | +$68M |
| CRM - Salesforce | 1.51% | Reduce −29.4% | 1,113,638 | $254.13 | $283M | −464,277 | −$145M |
| ABBV - Abbvie | 1.16% | Add +233.8% | 1,608,451 | $135.40 | $218M | +1,126,603 | +$166M |
| ADBE - Adobe Systems | 1.14% | New | 376,000 | $567.06 | $213M | +376,000 | +$213M |
| CHTR - Charter Communications · CL A | 1.10% | Reduce −17.1% | 315,701 | $651.97 | $206M | −65,300 | −$71M |
| ALNY - Alnylam Pharmaceuticals | 1.08% | Add +46.1% | 1,190,028 | $169.58 | $202M | +375,727 | +$48M |
| BEAM - Beam Therapeutics | 0.96% | Add +31.9% | 2,265,045 | $79.69 | $181M | +547,455 | +$31M |
| EXEL - Exelixis | 0.86% | Reduce −8.3% | 8,859,157 | $18.28 | $162M | −800,555 | −$42M |
| AVTR - Avantor | 0.82% | Add +11.6% | 3,642,858 | $42.14 | $154M | +377,707 | +$20M |
| Horizon Therapeutics Pub L | 0.80% | Add +19.1% | 1,396,217 | $107.76 | $150M | +224,043 | +$22M |
| NTRA - Natera | 0.73% | Add +13.3% | 1,472,715 | $93.39 | $138M | +172,581 | −$7M |
| CVS - Cvs Health | 0.71% | Add +447.6% | 1,281,456 | $103.16 | $132M | +1,047,456 | +$112M |
| Laboratory Amer | 0.69% | Add +16.4% | 414,169 | $314.21 | $130M | +58,298 | +$30M |
| ENTA - Enanta Pharmaceuticals | 0.63% | Reduce −21.1% | 1,573,829 | $74.78 | $118M | −421,171 | +$4M |
| YMM - Full Truck Alliance | 0.63% | Add +1618.7% | 14,007,743 | $8.37 | $117M | +13,192,743 | +$105M |
| IOVA - Iovance Biotherapeutics | 0.62% | Add +13.5% | 6,061,973 | $19.09 | $116M | +721,979 | −$16M |
| AZNN — | 0.59% | Add +470.7% | 1,906,155 | $58.25 | $111M | +1,572,155 | +$91M |
| Lufax · CL A | 0.57% | Add +32.5% | 19,019,399 | $5.63 | $107M | +4,662,500 | +$7M |
| CYTK - Cytokinetics | 0.53% | Reduce −20.6% | 2,170,342 | $45.58 | $99M | −562,433 | +$1M |
| Catalent | 0.52% | Reduce −17.9% | 763,561 | $128.03 | $98M | −166,638 | −$26M |
| Blueprint Medicines | 0.46% | Reduce −14.0% | 811,747 | $107.11 | $87M | −132,656 | −$10M |
| PCG - Pg And E | 0.41% | Reduce −13.5% | 6,305,142 | $12.14 | $77M | −986,900 | +$7M |
| Sarepta Therapeutics | 0.40% | Add +417.9% | 839,009 | $90.05 | $76M | +677,009 | +$61M |
| Karuna Therapeutics | 0.38% | Reduce −21.4% | 550,000 | $131.00 | $72M | −150,000 | −$14M |
| UTHR - United Therapeutics | 0.37% | New | 320,760 | $216.08 | $69M | +320,760 | +$69M |
| RVMD - Revolution Medicines | 0.37% | Hold | 2,750,000 | $25.17 | $69M | — | — |
| PTGX - Protagonist Therapeutics | 0.35% | Reduce −19.9% | 1,917,134 | $34.20 | $66M | −474,866 | +$23M |
| BRKR - Bruker | 0.33% | New | 745,266 | $83.91 | $63M | +745,266 | +$63M |
| Amyris | 0.31% | Reduce −7.3% | 10,859,811 | $5.41 | $59M | −859,114 | −$102M |
| Imago Biosciences | 0.31% | Reduce −7.5% | 2,471,313 | $23.71 | $59M | −200,000 | +$5M |
| Atento S A | 0.30% | Hold | 2,230,357 | $25.53 | $57M | — | — |
| JAZZ - Jazz Pharmaceuticals | 0.29% | Reduce −25.0% | 431,021 | $127.40 | $55M | −143,886 | −$20M |
| Broadmark Rlty Cap | 0.24% | Reduce −2.1% | 4,850,000 | $9.43 | $46M | −106,174 | −$3M |
| Qiagen | 0.24% | Reduce −44.8% | 814,064 | $55.58 | $45M | −659,784 | −$31M |
| Zogenix | 0.24% | Hold | 2,766,935 | $16.25 | $45M | — | — |
| Zendesk | 0.24% | New | 430,000 | $104.29 | $45M | +430,000 | +$45M |
| CRBU - Caribou Biosciences | 0.24% | Hold | 2,963,448 | $15.09 | $45M | — | — |
| FATE - Fate Therapeutics | 0.24% | Reduce −67.2% | 757,425 | $58.51 | $44M | −1,553,973 | −$93M |
| PACB — | 0.22% | Add +2.7% | 2,045,488 | $20.46 | $42M | +53,238 | −$9M |
| AGIO - Agios Pharmaceuticals | 0.22% | Add +53.5% | 1,256,578 | $32.87 | $41M | +437,811 | +$4M |
| RGEN - Repligen | 0.19% | Add +49.6% | 136,245 | $264.84 | $36M | +45,175 | +$10M |
| BIIB - Biogen | 0.19% | Reduce −13.5% | 147,709 | $239.92 | $35M | −23,150 | −$13M |
| Chemocentryx | 0.18% | Add +142.3% | 935,463 | $36.41 | $34M | +549,463 | +$27M |
| Marblegate Acquisition · CL A | 0.15% | New | 2,970,000 | $9.77 | $29M | +2,970,000 | +$29M |
| BEKE - KE | 0.15% | Add +411.7% | 1,397,000 | $20.12 | $28M | +1,124,000 | +$23M |
| Holding · CL A | 0.15% | Hold | 2,809,000 | $9.76 | $27M | — | — |
| Exact Sciences | 0.13% | Reduce −46.1% | 321,898 | $77.83 | $25M | −275,700 | −$32M |
| Generation Bio | 0.13% | Hold | 3,500,000 | $7.08 | $25M | — | — |
| Cara Therapeutics | 0.13% | Hold | 2,000,000 | $12.18 | $24M | — | — |
| Austerlitz Acquisition · CL A | 0.13% | Add +1.8% | 2,500,000 | $9.71 | $24M | +43,113 | −$146K |
| Berenson Acquisition I · CL A | 0.13% | New | 2,475,000 | $9.67 | $24M | +2,475,000 | +$24M |
| Metals Acquisition · CL A | 0.13% | New | 2,475,000 | $9.65 | $24M | +2,475,000 | +$24M |
| QTRX - Quanterix | 0.12% | Hold | 545,000 | $42.40 | $23M | — | — |
| Ventyx Biosciences | 0.12% | New | 1,114,280 | $19.86 | $22M | +1,114,280 | +$22M |
| GPOR - Gulfport Energy | 0.11% | Reduce −8.0% | 296,372 | $72.03 | $21M | −25,747 | −$5M |
| ARWR - Arrowhead Pharmaceuticals | 0.11% | Reduce −59.8% | 320,617 | $66.30 | $21M | −475,961 | −$28M |
| Somalogic · CLASS A | 0.11% | Reduce −69.0% | 1,808,907 | $11.64 | $21M | −4,017,566 | −$51M |
| Holding · CL A | 0.11% | Hold | 1,000,000 | $19.72 | $20M | — | — |
| Swiftmerge Acquisition | 0.11% | New | 1,980,000 | $9.94 | $20M | +1,980,000 | +$20M |
| Revolution Healthcar Aq · CLASS A | 0.10% | Hold | 2,000,000 | $9.71 | $19M | — | — |
| Holding · CLASS A | 0.10% | New | 1,900,000 | $9.64 | $18M | +1,900,000 | +$18M |
| Holding · CL A | 0.09% | Hold | 1,750,000 | $9.75 | $17M | — | — |
| Holding · CLASS A | 0.09% | Hold | 1,732,500 | $9.80 | $17M | — | — |
| Ready Capital | 0.09% | Reduce −13.5% | 1,080,961 | $15.63 | $17M | −169,265 | −$1M |
| Sdcl Edge Acquisition · CL A | 0.09% | New | 1,732,500 | $9.74 | $17M | +1,732,500 | +$17M |
| Vector Acquisition Ii · CL A | 0.09% | Add +126.7% | 1,700,000 | $9.77 | $17M | +950,000 | +$9M |
| Shelter Acquisition I · CLASS A | 0.09% | Hold | 1,650,000 | $9.75 | $16M | — | — |
| Big Sky Growth Partners · CLASS A | 0.08% | Hold | 1,550,000 | $9.71 | $15M | — | — |
| KKR - Kkr Acquisition I · CLASS A | 0.08% | Hold | 1,500,000 | $9.74 | $15M | — | — |
| Radius Health | 0.08% | Hold | 2,107,400 | $6.92 | $15M | — | — |
| Holding · CL A | 0.08% | Hold | 1,500,000 | $9.72 | $15M | — | — |
| Berkeley Lts | 0.08% | New | 787,327 | $18.18 | $14M | +787,327 | +$14M |
| Ares Acquisition · CL A | 0.07% | Add +42.5% | 1,425,000 | $9.74 | $14M | +425,000 | +$4M |
| Humanco Acquisition · CL A | 0.07% | Add +176.6% | 1,407,749 | $9.78 | $14M | +898,849 | +$9M |
| Disruptive Acquisition · CLASS A | 0.07% | Hold | 1,400,000 | $9.80 | $14M | — | — |
| Ikena Oncology | 0.07% | Reduce −3.2% | 1,081,309 | $12.54 | $14M | −36,040 | −$9M |
| Holding · CLASS A | 0.07% | Add +36.0% | 1,360,040 | $9.95 | $14M | +360,040 | +$4M |
| Fibrogen | 0.07% | Reduce −36.4% | 919,117 | $14.10 | $13M | −527,095 | −$2M |
| Holding · CL A | 0.06% | Hold | 1,250,000 | $9.73 | $12M | — | — |
| NUVB - Nuvation Bio · CL A | 0.06% | Reduce −35.3% | 1,430,000 | $8.50 | $12M | −780,000 | −$10M |
| Tcv Acquisition · CL A | 0.06% | Add +142.3% | 1,211,459 | $9.86 | $12M | +711,459 | +$7M |
| Holding · CL A | 0.06% | Add +61.1% | 1,208,326 | $9.77 | $12M | +458,326 | +$4M |
| Nightdragon Acquisition · CLASS A | 0.06% | Add +200.0% | 1,200,000 | $9.75 | $12M | +800,000 | +$8M |
| Agile Growth · CLASS A | 0.06% | Hold | 1,200,000 | $9.70 | $12M | — | — |
| Gores Vii · CL A | 0.06% | Add +53.4% | 1,150,162 | $9.78 | $11M | +400,162 | +$4M |
| Holding · CL A | 0.06% | Add +49.3% | 1,120,102 | $9.80 | $11M | +370,102 | +$4M |
| Gores Metropoulos Ii · CL A | 0.06% | Hold | 1,100,000 | $9.97 | $11M | — | — |
| Tpg Pace Beneficial Ii | 0.06% | Add +48.9% | 1,116,833 | $9.80 | $11M | +366,833 | +$4M |
| Tiga Acquisition · CL A | 0.06% | Hold | 1,080,000 | $10.13 | $11M | — | — |
| Zealand Pharma A/S | 0.06% | Hold | 510,000 | $21.34 | $11M | — | — |
| Holding · CL A | 0.05% | Hold | 1,000,000 | $9.89 | $10M | — | — |
| Holding · CL A | 0.05% | Hold | 1,000,000 | $9.87 | $10M | — | — |
| Cascade Acquisition · CL A | 0.05% | Hold | 990,000 | $9.94 | $10M | — | — |
| Churchill Capital Vii · CL A | 0.05% | Hold | 1,000,000 | $9.83 | $10M | — | — |
| Holding · CLASS A | 0.05% | Hold | 1,000,000 | $9.78 | $10M | — | — |
| Forum Merger Iv · CLASS A | 0.05% | Hold | 1,000,000 | $9.74 | $10M | — | — |
| Savara | 0.05% | Add +19.3% | 7,770,262 | $1.24 | $10M | +1,258,176 | +$648K |
| RCEL - Avita Medical | 0.05% | Hold | 800,000 | $11.98 | $10M | — | — |
| Point Biopharma Global | 0.05% | Reduce −25.5% | 1,706,329 | $5.60 | $10M | −583,671 | −$8M |
| Clever Leaves | 0.05% | Add +19.9% | 3,049,853 | $3.10 | $9M | +506,086 | −$10M |
| Holding | 0.05% | New | 900,000 | $10.15 | $9M | +900,000 | +$9M |
| Interprivate Ii Acquisition · CL A | 0.05% | Add +120.7% | 882,647 | $9.70 | $9M | +482,647 | +$5M |
| Exscientia | 0.04% | New | 425,000 | $19.76 | $8M | +425,000 | +$8M |
| Holding · CLASS A | 0.04% | Add +40.5% | 843,046 | $9.90 | $8M | +243,046 | +$2M |
| Rxr Acquisition · CLASS A | 0.04% | Add +42.5% | 854,961 | $9.75 | $8M | +254,961 | +$3M |
| Holding | 0.04% | Add +6.0% | 848,184 | $9.80 | $8M | +48,184 | +$600K |
| Holding · CL A | 0.04% | Add +16.1% | 825,100 | $9.90 | $8M | +114,649 | +$1M |
| Holding · CLASS A | 0.04% | Add +10.8% | 835,638 | $9.74 | $8M | +81,738 | +$788K |
| Arya Sciences Acqu Iv · CL A | 0.04% | Hold | 800,000 | $9.93 | $8M | — | — |
| VCYT - Veracyte | 0.04% | Add +3.2% | 191,158 | $41.20 | $8M | +5,936 | −$728K |
| Landcadia Iv · CLASS A | 0.04% | Add +60.4% | 802,028 | $9.74 | $8M | +302,028 | +$3M |
| Holding · CL A | 0.04% | Hold | 800,000 | $9.75 | $8M | — | — |
| Levere · CLASS A | 0.04% | Hold | 800,000 | $9.74 | $8M | — | — |
| Churchill Capital Vi · CL A | 0.04% | Add +95.7% | 782,767 | $9.78 | $8M | +382,767 | +$4M |
| Holding · CL A | 0.04% | New | 775,200 | $9.83 | $8M | +775,200 | +$8M |
| Holding | 0.04% | New | 750,000 | $10.03 | $8M | +750,000 | +$8M |
| Holding · CLASS A | 0.04% | Hold | 750,000 | $9.98 | $7M | — | — |
| Social Leverage Acquisn · CL A | 0.04% | Hold | 750,000 | $9.81 | $7M | — | — |
| Holding · CL A | 0.04% | Hold | 750,000 | $9.78 | $7M | — | — |
| Holding · CL A | 0.04% | Hold | 750,000 | $9.76 | $7M | — | — |
| Research Alliance Ii · CL A | 0.04% | Hold | 750,000 | $9.72 | $7M | — | — |
| Panacea Acquisition Ii · CL A | 0.04% | Hold | 750,000 | $9.70 | $7M | — | — |
| Pathfinder Acquisition · CL A | 0.04% | Hold | 750,000 | $9.70 | $7M | — | — |
| Holding · CLASS A | 0.04% | Hold | 745,000 | $9.69 | $7M | — | — |
| Gores Viii · CL A | 0.04% | Add +73.2% | 692,810 | $10.20 | $7M | +292,810 | +$3M |
| Dariohealth | 0.04% | Hold | 540,000 | $12.97 | $7M | — | — |
| Corsair Partnering · CL A | 0.04% | Hold | 700,000 | $9.76 | $7M | — | — |
| Holding · CL A | 0.04% | Hold | 700,000 | $9.75 | $7M | — | — |
| Khosla Ventures Acquisition · CL A | 0.04% | Hold | 700,000 | $9.70 | $7M | — | — |
| Theseus Pharmaceuticals | 0.04% | New | 523,979 | $12.68 | $7M | +523,979 | +$7M |
| Rocket Internet Grwt Oprt · CL A | 0.03% | Add +29.6% | 647,945 | $9.80 | $6M | +147,945 | +$1M |
| Better Therapeutics | 0.03% | New | 1,350,000 | $4.65 | $6M | +1,350,000 | +$6M |
| Holding · CL A | 0.03% | Hold | 600,000 | $10.25 | $6M | — | — |
| Rcf Acquisition | 0.03% | New | 600,000 | $10.10 | $6M | +600,000 | +$6M |
| Holding · CLASS A | 0.03% | Hold | 600,000 | $9.76 | $6M | — | — |
| Finserv Acquisition Ii · CL A | 0.03% | Hold | 600,000 | $9.72 | $6M | — | — |
| Blue Whale Acquisition · CLASS A | 0.03% | New | 575,000 | $9.69 | $6M | +575,000 | +$6M |
| SLAM · CL A | 0.03% | Add +709.0% | 570,396 | $9.75 | $6M | +499,888 | +$5M |
| ANNX - Annexon | 0.03% | Reduce −60.4% | 457,764 | $11.49 | $5M | −699,497 | −$16M |
| COGT - Cogent Biosciences | 0.03% | Hold | 600,000 | $8.58 | $5M | — | — |
| G Squared Ascend I · CL A | 0.03% | Hold | 500,000 | $9.88 | $5M | — | — |
| Ftac Hera Acquisition · CLASS A | 0.03% | Hold | 500,000 | $9.77 | $5M | — | — |
| Tio Tech A · CLASS A | 0.03% | Add +0.4% | 502,001 | $9.68 | $5M | +2,001 | +$14K |
| Holding · CL A | 0.03% | Hold | 500,000 | $9.71 | $5M | — | — |
| Holding · CL A | 0.03% | Add +93.9% | 484,709 | $9.77 | $5M | +234,709 | +$2M |
| Holding · CLASS A | 0.02% | Add +81.0% | 452,519 | $9.91 | $4M | +202,519 | +$2M |
| Scion Tech Growth Ii · CL A | 0.02% | Hold | 450,000 | $9.73 | $4M | — | — |
| Ldh Growth I · CLASS A | 0.02% | Add +191.1% | 436,702 | $9.82 | $4M | +286,702 | +$3M |
| Svf Investment · CL A | 0.02% | Add +70.0% | 425,000 | $10.04 | $4M | +175,000 | +$2M |
| Holding · CLASS A | 0.02% | Hold | 425,000 | $9.81 | $4M | — | — |
| Lamf Global Ventures I | 0.02% | New | 400,000 | $10.04 | $4M | +400,000 | +$4M |
| Holding · CL A | 0.02% | Hold | 400,000 | $9.91 | $4M | — | — |
| Holding · CLASS A | 0.02% | Hold | 400,000 | $9.90 | $4M | — | — |
| Holding | 0.02% | Hold | 810,500 | $4.84 | $4M | — | — |
| Lianbio | 0.02% | New | 600,000 | $6.16 | $4M | +600,000 | +$4M |
| Holding | 0.02% | New | 350,000 | $10.15 | $4M | +350,000 | +$4M |
| Uta Acquisition | 0.02% | New | 350,000 | $10.05 | $4M | +350,000 | +$4M |
| TNGX - Tango Therapeutics | 0.02% | Hold | 300,000 | $10.94 | $3M | — | — |
| CMPX - Compass Therapeutics | 0.02% | New | 1,000,000 | $3.17 | $3M | +1,000,000 | +$3M |
| Holding | 0.02% | New | 300,000 | $10.11 | $3M | +300,000 | +$3M |
| Holding · CL A | 0.02% | Hold | 304,698 | $9.84 | $3M | — | — |
| Lazard Growth Acquisition · CL A | 0.02% | Hold | 300,000 | $9.73 | $3M | — | — |
| Avrobio | 0.02% | Hold | 740,000 | $3.85 | $3M | — | — |
| Holding | 0.01% | New | 86,454 | $29.28 | $3M | +86,454 | +$3M |
| Surface Oncology | 0.01% | Reduce −48.0% | 520,021 | $4.78 | $2M | −479,979 | −$5M |
| Broadscale Acquisition · CL A | 0.01% | New | 250,000 | $9.94 | $2M | +250,000 | +$2M |
| Live Oak Mobility Acquisi · CL A | 0.01% | Hold | 250,000 | $9.77 | $2M | — | — |
| Hudson Executive Inves Iii · CL A | 0.01% | Hold | 250,000 | $9.72 | $2M | — | — |
| Arctos Northstar Acquis · CL A | 0.01% | Hold | 200,000 | $9.74 | $2M | — | — |
| Holding · CL A | 0.01% | Reduce −11.2% | 177,580 | $10.29 | $2M | −22,420 | −$117K |
| Priveterra Acquisition · CL A | 0.01% | Hold | 150,000 | $9.72 | $1M | — | — |
| The Music Acquisition · CLASS A | 0.01% | Hold | 125,000 | $9.76 | $1M | — | — |
| Crypto 1 Acquisition | 0.01% | New | 100,000 | $10.10 | $1M | +100,000 | +$1M |
| NTRS - Northern Trust · CL A | 0.01% | Hold | 100,000 | $9.75 | $975K | — | — |
| NTRS - Northern Trust · CL A | 0.01% | Hold | 100,000 | $9.74 | $974K | — | — |
| OKLO - Altc Acquisition · CL A | 0.01% | New | 98,300 | $9.85 | $968K | +98,300 | +$968K |
| GRFS - Grifols S A | 0.00% | Hold | 53,133 | $11.22 | $596K | — | — |
| Holding · CL A | 0.00% | Hold | 60,053 | $9.87 | $593K | — | — |
| Holding | 0.00% | Hold | 85,838 | $6.05 | $519K | — | — |
| Holding | 0.00% | Hold | 130,000 | $2.10 | $273K | — | — |
Showing top 50 of 202 by value
Exits / last held
not current holdings · last reported size, unchanged · gone vs 2021 Q3
| Stock | % of portfolio | Recent activity | Shares | Reported price* | Value | Share change | $ change |
|---|---|---|---|---|---|---|---|
| TMUS - T-Mobile US | 2.98% | Exit | 0 | $127.76 | $588M | −4,599,011 | −$588M |
| Acceleron Pharma | 1.89% | Exit | 0 | $172.10 | $373M | −2,164,663 | −$373M |
| WTW - Willis Towers Watson | 1.62% | Exit | 0 | $232.46 | $319M | −1,373,000 | −$319M |
| HLT - Hilton | 1.40% | Exit | 0 | $132.11 | $275M | −2,085,077 | −$275M |
| FIS - Fidelity Natl Info | 1.35% | Exit | 0 | $121.68 | $267M | −2,192,172 | −$267M |
| Macquarie Infrastr Hold | 0.90% | Exit | 0 | $40.56 | $177M | −4,361,050 | −$177M |
| Playa Hotels & Resorts | 0.35% | Exit | 0 | $8.29 | $69M | −8,352,553 | −$69M |
| BABA - Alibaba Group | 0.32% | Exit | 0 | $148.05 | $62M | −421,400 | −$62M |
| Ihs Markit | 0.30% | Exit | 0 | $116.62 | $60M | −514,900 | −$60M |
| Mirati Therapeutics | 0.21% | Exit | 0 | $176.91 | $42M | −238,718 | −$42M |
| Arena Pharmaceuticals | 0.20% | Exit | 0 | $59.55 | $39M | −656,548 | −$39M |
| NEO - Neogenomics | 0.13% | Exit | 0 | $48.24 | $26M | −529,839 | −$26M |
| Metals Acquisition | 0.12% | Exit | 0 | $9.91 | $25M | −2,475,000 | −$25M |
| Berenson Acquisition I | 0.12% | Exit | 0 | $9.86 | $24M | −2,475,000 | −$24M |
| Holding · CLASS A | 0.10% | Exit | 0 | $10.05 | $20M | −2,000,000 | −$20M |
| Holding · CL A | 0.10% | Exit | 0 | $10.18 | $19M | −1,900,787 | −$19M |
| DKNG - Draftkings · CL A | 0.10% | Exit | 0 | $48.16 | $19M | −390,000 | −$19M |
| Holding | 0.10% | Exit | 0 | $9.88 | $19M | −1,900,000 | −$19M |
| FIVN - FIVE9 | 0.09% | Exit | 0 | $159.74 | $19M | −116,000 | −$19M |
| NVAX - Novavax | 0.09% | Exit | 0 | $207.32 | $17M | −83,713 | −$17M |
| Fs Development Ii · CL A | 0.05% | Exit | 0 | $9.95 | $10M | −1,000,000 | −$10M |
| QURE - Uniqure | 0.05% | Exit | 0 | $32.01 | $10M | −300,000 | −$10M |
| QSI - Quantum Si · CL A | 0.04% | Exit | 0 | $8.34 | $8M | −1,000,000 | −$8M |
| Holding | 0.04% | Exit | 0 | $10.20 | $8M | −775,200 | −$8M |
| Holding · CLASS A | 0.04% | Exit | 0 | $9.93 | $7M | −750,000 | −$7M |
| Cm Life Sciences Iii · CLASS A | 0.04% | Exit | 0 | $9.92 | $7M | −750,000 | −$7M |
| Blue Whale Acquisition | 0.03% | Exit | 0 | $10.01 | $6M | −575,000 | −$6M |
| Nextgen Acquisition Ii · CLASS A | 0.03% | Exit | 0 | $9.91 | $5M | −550,914 | −$5M |
| BCABGBP - Bioatla | 0.03% | Exit | 0 | $29.44 | $5M | −180,000 | −$5M |
| Tpg Pace Solutions · CL A | 0.02% | Exit | 0 | $10.05 | $4M | −350,000 | −$4M |
| Achilles Therapeutics | 0.02% | Exit | 0 | $7.79 | $4M | −450,000 | −$4M |
| NTRS - Northern Trust | 0.01% | Exit | 0 | $9.93 | $3M | −278,026 | −$3M |
| Orchard Therapeutics | 0.01% | Exit | 0 | $2.30 | $2M | −665,200 | −$2M |
| Cf Acquisition Vi · CL A | — | Exit | 0 | $9.71 | $971K | −100,000 | −$971K |
| Alpha Capital Acquisition · CL A | — | Exit | 0 | $9.72 | $774K | −79,598 | −$774K |
Filings history
20 periods · normalized AUM · open a period for holdings
| Period | Holdings | AUM | QoQ | Form | Filed | Filing ID |
|---|---|---|---|---|---|---|
| 2026 Q2 | 89 | $21.7B | +23.6% | 13F-HR | 8/14/2026 | 000090883426000432 |
| 2026 Q1 | 1 | $1.5B | — | new holds | 8/14/2026 | 000090883426000434 |
| 2026 Q1 | 172 | $17.5B | −17.2% | 13F-HR | 5/15/2026 | 000090883426000240 |
| 2025 Q4 | 1 | $1B | — | new holds | 8/14/2026 | 000090883426000433 |
| 2025 Q4 | 2 | $884M | — | new holds | 5/15/2026 | 000090883426000241 |
| 2025 Q4 | 151 | $21.2B | −13.2% | 13F-HR | 2/17/2026 | 000090883426000087 |
| 2025 Q3 | 144 | $24.4B | — | RESTATEMENT | 2/17/2026 | 000090883426000086 |
| 2025 Q3 | 144 | $24.4B | +5.4% | 13F-HR | 11/14/2025 | 000090883425000353 |
| 2025 Q2 | 1 | $140M | — | new holds | 2/17/2026 | 000090883426000085 |
| 2025 Q2 | 3 | $483M | — | new holds | 11/14/2025 | 000090883425000352 |
| 2025 Q2 | 141 | $23.2B | +29.2% | 13F-HR | 8/14/2025 | 000090883425000248 |
| 2025 Q1 | 1 | $274M | — | new holds | 2/17/2026 | 000090883426000084 |
| 2025 Q1 | 3 | $416M | — | new holds | 11/14/2025 | 000090883425000351 |
| 2025 Q1 | 7 | $2.2B | — | new holds | 8/14/2025 | 000090883425000247 |
| 2025 Q1 | 135 | $17.9B | −9.0% | 13F-HR | 5/15/2025 | 000090883425000177 |
| 2024 Q4 | 1 | $85M | — | new holds | 2/17/2026 | 000090883426000083 |
| 2024 Q4 | 2 | $349M | — | new holds | 11/14/2025 | 000090883425000350 |
| 2024 Q4 | 6 | $2.3B | — | new holds | 8/14/2025 | 000090883425000246 |
| 2024 Q4 | 4 | $333M | — | new holds | 5/15/2025 | 000090883425000180 |
| 2024 Q4 | 138 | $19.7B | −3.5% | 13F-HR | 2/14/2025 | 000090883425000081 |
| 2024 Q3 | 1 | $145M | — | new holds | 11/14/2025 | 000090883425000349 |
| 2024 Q3 | 6 | $1.5B | — | new holds | 8/14/2025 | 000090883425000243 |
| 2024 Q3 | 3 | $216M | — | new holds | 5/15/2025 | 000090883425000179 |
| 2024 Q3 | 2 | $544M | — | new holds | 2/14/2025 | 000090883425000080 |
| 2024 Q3 | 153 | $20.4B | −3.6% | 13F-HR | 11/14/2024 | 000090883424000307 |
| 2024 Q2 | 1 | $120M | — | new holds | 11/14/2025 | 000090883425000348 |
| 2024 Q2 | 5 | $1.2B | — | new holds | 8/14/2025 | 000090883425000245 |
| 2024 Q2 | 1 | $199M | — | new holds | 5/15/2025 | 000090883425000178 |
| 2024 Q2 | 2 | $452M | — | new holds | 2/14/2025 | 000090883425000079 |
| 2024 Q2 | 1 | $149M | — | new holds | 11/14/2024 | 000090883424000324 |
| 2024 Q2 | 157 | $21.2B | −4.2% | 13F-HR | 8/14/2024 | 000090883424000200 |
| 2024 Q1 | 1 | $93M | — | new holds | 11/14/2025 | 000090883425000347 |
| 2024 Q1 | 4 | $1.2B | — | new holds | 8/14/2025 | 000090883425000244 |
| 2024 Q1 | 2 | $159M | — | new holds | 2/14/2025 | 000090883425000078 |
| 2024 Q1 | 1 | $45M | — | new holds | 8/14/2024 | 000090883424000202 |
| 2024 Q1 | 167 | $22.1B | — | RESTATEMENT | 5/24/2024 | 000090883424000159 |
| 2024 Q1 | 167 | $22.1B | +9.8% | 13F-HR | 5/15/2024 | 000090883424000135 |
| 2023 Q4 | 1 | $65M | — | new holds | 11/14/2025 | 000090883425000346 |
| 2023 Q4 | 2 | $548M | — | new holds | 8/14/2025 | 000090883425000250 |
| 2023 Q4 | 5 | $1.1B | — | new holds | 5/15/2024 | 000090883424000141 |
| 2023 Q4 | 150 | $20.1B | +1.0% | 13F-HR | 2/14/2024 | 000090883424000070 |
| 2023 Q3 | 1 | $40M | — | new holds | 11/14/2025 | 000090883425000345 |
| 2023 Q3 | 1 | $40M | — | new holds | 5/15/2024 | 000090883424000138 |
| 2023 Q3 | 2 | $1.4B | — | new holds | 2/14/2024 | 000090883424000077 |
| 2023 Q3 | 1 | $1.9B | — | new holds | 2/12/2024 | 000090883424000049 |
| 2023 Q3 | 159 | $20B | +11.5% | 13F-HR | 11/14/2023 | 000090883423000150 |
| 2023 Q2 | 2 | $669M | — | new holds | 2/14/2024 | 000090883424000076 |
| 2023 Q2 | 5 | $1.4B | — | new holds | 11/14/2023 | 000090883423000157 |
| 2023 Q2 | 1 | $1.2B | — | new holds | 10/26/2023 | 000090883423000134 |
| 2023 Q2 | 165 | $17.9B | +1.3% | 13F-HR | 8/14/2023 | 000090883423000109 |
| 2023 Q1 | 2 | $234M | — | new holds | 2/14/2024 | 000090883424000075 |
| 2023 Q1 | 3 | $389M | — | new holds | 11/14/2023 | 000090883423000156 |
| 2023 Q1 | 1 | $15M | — | new holds | 8/14/2023 | 000090883423000110 |
| 2023 Q1 | 187 | $17.7B | +15.8% | 13F-HR | 5/15/2023 | 000117570723000127 |
| 2022 Q4 | 1 | $171M | — | new holds | 2/14/2024 | 000090883424000074 |
| 2022 Q4 | 3 | $485M | — | new holds | 11/14/2023 | 000090883423000155 |
| 2022 Q4 | 7 | $1B | — | new holds | 5/15/2023 | 000117570723000136 |
| 2022 Q4 | 232 | $15.3B | −9.3% | 13F-HR | 2/14/2023 | 000117570723000051 |
| 2022 Q3 | 1 | $125M | — | new holds | 2/14/2024 | 000090883424000073 |
| 2022 Q3 | 3 | $415M | — | new holds | 11/14/2023 | 000090883423000154 |
| 2022 Q3 | 5 | $411M | — | new holds | 5/15/2023 | 000117570723000135 |
| 2022 Q3 | 4 | $434M | — | new holds | 2/14/2023 | 000090966123000005 |
| 2022 Q3 | 298 | $16.8B | +3.5% | 13F-HR | 11/14/2022 | 000156761922019851 |
| 2022 Q2 | 1 | $115M | — | new holds | 2/14/2024 | 000090883424000081 |
| 2022 Q2 | 3 | $411M | — | new holds | 11/14/2023 | 000090883423000153 |
| 2022 Q2 | 2 | $337M | — | new holds | 5/15/2023 | 000117570723000134 |
| 2022 Q2 | 3 | $136M | — | new holds | 2/14/2023 | 000090966123000003 |
| 2022 Q2 | 9 | $1.2B | — | new holds | 11/14/2022 | 000156761922019862 |
| 2022 Q2 | 297 | $16.3B | −13.7% | 13F-HR | 8/15/2022 | 000156761922015953 |
| 2022 Q1 | 1 | $268M | — | new holds | 11/14/2023 | 000090883423000152 |
| 2022 Q1 | 1 | $314M | — | new holds | 5/15/2023 | 000117570723000133 |
| 2022 Q1 | 1 | $27M | — | new holds | 2/14/2023 | 000090966123000002 |
| 2022 Q1 | 3 | $186M | — | new holds | 11/14/2022 | 000156761922019864 |
| 2022 Q1 | 8 | $1.1B | — | new holds | 8/15/2022 | 000156761922015972 |
| 2022 Q1 | 307 | $18.8B | +0.4% | 13F-HR | 5/16/2022 | 000156761922010736 |
| 2021 Q4 | 1 | $227M | — | new holds | 5/15/2023 | 000117570723000132 |
| 2021 Q4 | 1 | $7M | — | new holds | 11/14/2022 | 000156761922019852 |
| 2021 Q4 | 1 | $115M | — | new holds | 8/15/2022 | 000156761922015968 |
| 2021 Q4 | 2 | $98M | — | new holds | 5/19/2022 | 000156761922011257 |
| 2021 Q4 | 6 | $833M | — | new holds | 5/16/2022 | 000156761922010757 |
| 2021 Q4 | 289 | $18.7B | −5.1% | 13F-HR | 2/14/2022 | 000156761922003965 |
| 2021 Q3 | 1 | $182M | — | new holds | 5/15/2023 | 000117570723000131 |
| 2021 Q3 | 1 | $105M | — | new holds | 8/15/2022 | 000156761922015964 |
| 2021 Q3 | 1 | $57M | — | new holds | 5/19/2022 | 000156761922011256 |
| 2021 Q3 | 3 | $998M | — | new holds | 5/16/2022 | 000156761922010753 |
| 2021 Q3 | 2 | $344M | — | new holds | 2/14/2022 | 000156761922003981 |
| 2021 Q3 | 293 | $19.7B | — | 13F-HR | 11/15/2021 | 000095012321015168 |
About
FARALLON CAPITAL MANAGEMENT, L.L.C.
87 processed 13Fs on this site · 2021 Q3–2026 Q2